Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Kohei Nakachi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7053-5778; OpenAlex author ID A5028933773, A5040581923. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
61
Papers, trials and grants by year

2011: 3 papers · 2012: 3 papers · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 10

  1. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  2. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  3. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  4. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). First author DOI 10.1016/j.ejca.2022.12.014↗
  5. Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer. Co-author DOI 10.1002/ijc.27594↗
  6. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Co-author DOI 10.1007/s00280-011-1786-6↗
  7. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  8. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. Co-author DOI 10.1007/s00534-011-0371-z↗
  9. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e3182021376↗
  10. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Last author DOI 10.1111/j.1349-7006.2010.01810.x↗

Closest collaborators

The 25 strongest of 61 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 9 shared papers, 2011–2025 · strength 0.75
  2. Junji Furuse · 6 shared papers, 2011–2025 · strength 0.67
  3. Makoto Ueno · 5 shared papers, 2012–2025 · strength 0.64
  4. Takeshi Terashima · 4 shared papers, 2023–2025 · strength 0.62
  5. Satoshi Kobayashi · 4 shared papers, 2023–2025 · strength 0.62
  6. Hiroshi Imaoka · 4 shared papers, 2023–2025 · strength 0.62
  7. Chigusa Morizane · 6 shared papers, 2011–2025 · strength 0.57
  8. Naohiro Okano · 3 shared papers, 2023–2025 · strength 0.45
  9. Akihiro Ohba · 3 shared papers, 2023–2025 · strength 0.45
  10. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  11. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  12. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  13. Kunihiro Tsuji · 2 shared papers, 2025 · strength 0.32
  14. Kumiko Umemoto · 2 shared papers, 2025 · strength 0.32
  15. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  16. Rei Suzuki · 2 shared papers, 2025 · strength 0.32
  17. Toshifumi Doi · 2 shared papers, 2025 · strength 0.32
  18. Reiko Ashida · 2 shared papers, 2025 · strength 0.32
  19. Hiroaki Nagano · 2 shared papers, 2025 · strength 0.32
  20. Yasuyuki Kawamoto · 2 shared papers, 2025 · strength 0.32
  21. Noritoshi Kobayashi · 2 shared papers, 2025 · strength 0.32
  22. Hiroshi Ohyama · 2 shared papers, 2025 · strength 0.32
  23. Shinya Kawaguchi · 2 shared papers, 2025 · strength 0.32
  24. Masato Ozaka · 2 shared papers, 2023–2024 · strength 0.29
  25. Takuji Okusaka · 5 shared papers, 2011–2023 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.